Novo Nordisk A/S Price Today
Novo Nordisk A/S
NVO
Healthcare
$354.16B
💰
Market Cap
38.6
💸
Price to Earnings
$4.1
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
13 |
Strong Buy |
6 |
Hold |
10 |
Sell |
2 |
Strong Sell |
1 |
NVO Price Forecast Target
156.6 👉 195.2 +25%
NVO EPS Forecast
4.1 👉 5.7 +39%
Financials
Profit Margin
32 %
Revenue Growth
27.0 %
Dividend
$ 1.76
Held Percent
0.0% - Insiders
8.2% - Institutions
91.8% - Public
Major Fund Holders
-
💰 Jennison Associates LLC $1.9B
-
💰 Renaissance Technologies, LLC $1.7B
-
💰 Fisher Asset Management, LLC $1.3B
-
💰 Bank of America Corporation $1.0B
-
💰 Envestnet Asset Management $844.9M
Stock Ideas
Nelson Peltz Portfolio
Nelson Peltz is a renowned investor known for his astute investment strategies and activist approach. With a portfolio spanning diverse industries, Peltz strategically targets underperforming companies, advocating for changes that unlock their full …
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Chase Coleman Portfolio
Chase Coleman, the young and accomplished founder of Tiger Global, has made a significant impact in the investment world. With initial funding from Julian Robertson, Coleman's Tiger Global Management delivered impressive returns, including a remarka…
Andreas Halvorsen Portfolio
Andreas Halvorsen is a Norwegian billionaire investor, hedge fund manager, and the founder of Viking Global Investors, a large hedge fund with over $50 billion in assets under management. He is known for his long-term, value-oriented investment appr…📮FAQ
Some Frequently Asked Questions.
The Novo Nordisk A/S industry is Biotechnology
The Novo Nordisk A/S sector is Healthcare
The Novo Nordisk A/S forecasted predicted Price to Earnings PE ratio is 27.7
The Novo Nordisk A/S Price to Earnings PE ratio is 38.6
The Market Capitalization of Novo Nordisk A/S is $354.16B
There are total of 12893087488 float shares with 8.2% held by Institutions and 0.0% held by insiders
The MNovo Nordisk A/S forecasted Earnings per Share EPS is $5.7
The Novo Nordisk A/S Earnings per Share EPS is 4.1
The Novo Nordisk A/S company has $148506000000 gross profits with 32 profit margins
The Novo Nordisk A/S Earnings Growth is 0.412% with 0.394% quarterly earnings growth
The Novo Nordisk A/S Revenue is $188290007040 with 0.27 revenue growth
The price target for Novo Nordisk A/S stock is $195.2 for the high target and $160.6 for the low target
The consensus analyst recommendations for Novo Nordisk A/S is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Novo Nordisk A/S is Buy, with the following breakdown:
- Buy: 13
- Strong Buy: 6
- Hold: 10
- Sell: 2
- Strong Sell: 1
The Beta of Novo Nordisk A/S is 0.3
The dividend of Novo Nordisk A/S is $1.76
The dividend yield of Novo Nordisk A/S is 0.0112%
The biggest institutional and mutual fund holders of Novo Nordisk A/S stock are
- Jennison Associates LLC
- Renaissance Technologies, LLC
- Fisher Asset Management, LLC
- Bank of America Corporation
The Novo Nordisk A/S ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0